Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. - Wikidata - wikimedia - TriplyDB

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

http://www.wikidata.org/entity/Q33375062

about

Fetomaternal alloimmune thrombocytopenia: the questions that still remain.Severe HPA-15b related neonatal alloimmune thrombocytopenia.Immunologic and structural analysis of eight novel domain-deletion beta3 integrin peptides designed for detection of HPA-1 antibodies.Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.Fc receptors in immune thrombocytopenias: a target for immunomodulation?Prenatal treatment of fetomaternal thrombocytopenia.Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention.Detection of human platelet antigen-1a alloantibodies in cases of fetomaternal alloimmune thrombocytopenia using recombinant β3 integrin fragments coupled to fluorescently labeled beads.A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry.The bleeding child. Part I: primary hemostatic disorders.How I manage neonatal thrombocytopenia.The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies.Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model.A review of the contemporary management of fetal and neonatal alloimmune thrombocytopenia in an Australian tertiary obstetric hospital.Foetal-neonatal alloimmune thrombocytopenia due to anti-HPA-2b antibodies present in the serum of a mother initially mistyped as HPA-1a negative Review of neonatal alloimmune thrombocytopenia.Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries Massive intracranial hemorrhage caused by neonatal alloimmune thrombocytopenia associated with anti-group A antibody.The implementation of surface plasmon resonance technique in monitoring pregnancies with expected fetal and neonatal alloimmune thrombocytopenia.Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management.Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia.Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers Sensitivity of assays for the detection of HPA-1a antibodies: results of an international workshop demonstrating the impact of cation chelation from integrin αIIbβ3 on three widely used assays.Human platelet antigen alleles in 998 Taiwanese blood donors determined by sequence-specific primer polymerase chain reaction.Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin.Low-frequency human platelet antigens as triggers for neonatal alloimmune thrombocytopenia.Noninvasive fetal genotyping of human platelet antigen-1a using targeted massively parallel sequencing.A multicenter validation of recombinant β3 integrin-coupled beads to detect human platelet antigen-1 alloantibodies in 498 cases of fetomaternal alloimmune thrombocytopenia.Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage.Further observations on the clinical significance and inheritance of the low-frequency platelet antigen HPA-28bw.Severe bleeding complications other than intracranial hemorrhage in neonatal alloimmune thrombocytopenia: a case series and review of the literature.The human platelet alloantigen profile in blood donors from Amazonas, Brazil.Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort Contemporary management of neonatal alloimmune thrombocytopenia: good outcomes in the intravenous immunoglobulin era: results from the Australian neonatal alloimmune thrombocytopenia registry.HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia.Human platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization.Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.Molecular typing of human platelet antigens in immune thrombocytopenia patients in northern Brazil.Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies.One size will never fit all: the future of research in pediatric transfusion medicine.

P2860

Q33376261-6415F7FB-8D28-4E73-929A-92EBCF3A0C2B Q33376647-5CFFA84E-AE7C-4714-A3B5-A429C551E123 Q33377595-07AD5CD9-C565-4D95-AFA5-325D956CAA85 Q33380492-AE75AFE5-D1A8-4CB9-88EB-8F04E7C3462A Q33380494-A5D06668-9432-479B-8F24-6A1A5CCD1B47 Q33387875-40ACF395-A5D2-409F-9A64-530E1DD87638 Q33392862-BBE6B3F4-46DF-464D-9500-737A9829A9ED Q33393340-93D37997-9802-4B85-BC64-0E888FDB6F40 Q33395614-8C3CE5B5-D69D-49C6-9599-7A24A5BF2082 Q33396419-6AA47966-1D55-4936-9E69-B62F626E70E1 Q33397361-EA802CB4-5C30-453C-8B16-3CBD2F00A87E Q33397768-2638AA00-306B-411F-8BFE-500F50E48DF0 Q33399223-1D7347A2-DA55-445C-B4F9-B89E5B0F261A Q33400790-98A7D2E3-F896-48A0-B273-892072C2B797 Q33401724-8E457C93-BBD8-48B7-9E13-3536EA6C8F8C Q33403261-DB063B53-3D25-45BE-84A0-A1F53670D4AF Q33403517-BCB8D8BA-1F87-4BAD-8E2D-35F980DE9FEE Q33404992-1D3F4DAE-354E-48EE-AD7C-C8490F467391 Q33405050-8EBD7904-2F5E-4642-AAE9-69F58529EEB8 Q33405694-68AC2618-CB56-4880-8F5A-815DDA28BA6E Q33407495-9301F0E9-B228-4822-A1BF-45FDE2CA08C6 Q33407552-8DD2E553-71B1-42E4-8DD6-819BB8A5C0DF Q33407595-AFCB1D5D-9037-4D17-B544-D8B659897B60 Q33409180-800C628F-96CA-4D0E-A876-745C583E1977 Q33409227-77670D6D-EC31-490A-9013-4816615DE8B2 Q33410953-4CD67E61-BB23-4574-963D-A9F35B6D624D Q33421975-33680D4E-0EF8-45C6-A6ED-ED70AE21FA90 Q33424394-8519B02B-0AB4-4EB8-AF0B-5789600D620C Q33426745-293FF662-AB94-41C3-BA0D-7DEEACB530A9 Q33428252-3F661987-0481-444C-A22C-26D87033E17E Q33430885-7A2EEC36-DCDC-47E2-937D-A1EE20FA17A9 Q33434661-CE160A03-A873-440F-AD1A-90D4C660F22C Q33435947-A5F605F7-D5D2-4D04-A300-6BF29E3EAB63 Q33436491-F68DBCC3-32C4-4D3B-A173-999CEB489A5D Q33437901-874C836F-CCE3-477D-A9DA-9EF1DB376F81 Q33440153-DFDC17DE-D9AA-4123-8FD0-52B45C28945D Q33441520-2F5BF88F-8E7F-47DB-8717-23D2CE8C2162 Q33442390-C1B08D18-05B8-41DD-AB33-5CAD3775D97E Q33442939-46CC371A-C258-4588-9AA3-CC65323E9E1B Q35535157-62451727-2F17-4735-8236-4A7896186746

P2860

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

http://www.wikidata.org/entity/Q33375062

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

@ast

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

@en

type

label

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

@ast

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

@en

prefLabel

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

@ast

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

@en

P1433

Q33375062-7205391E-43DB-47D0-BA68-DB26C72479E9

P1476

Q33375062-E3F2AFA9-5291-4296-889D-0096AE0081E9

P2093

Q33375062-146ECDD9-A329-4088-96BC-C8B0C38E54A5

Q33375062-1C2F2C3B-BFB5-4A6E-980C-3179A71BBA17

Q33375062-249C9C78-6092-4B88-8BA7-4BAAFF05A45D

Q33375062-86300B59-FC2D-427E-B457-625822F0B67A

Q33375062-9A79585C-EE0C-4F4A-AAC8-59A124CC7F34

Q33375062-CC4CA0AB-85F6-43F0-889A-1CBFCC5BFC00

Q33375062-CD35C16B-ECAF-4CF4-8BD7-7F6AD755DF41

P2860

Q33375062-02D533AB-EAB7-4690-98DC-4D83B13B5F45

Q33375062-05827973-1FFD-4F84-B9EF-2F98C6489871

Q33375062-10B980CE-1A7F-4EF0-B2DA-8E80640B194C

Q33375062-1A1069E9-7DFE-49FC-8B63-911737DD1728

Q33375062-1E8FDA48-7145-4B7B-AFFF-E4524CA2FC54

Q33375062-30BCFF98-A011-4930-83B2-BB895DEED4F7

Q33375062-30DABDD9-A607-48E6-B8E1-C516713E44E6

Q33375062-3C7CEB7B-4EF6-4EA3-9443-C13EF3C38BCD

Q33375062-54D9634F-FDA8-4ED5-BCA3-23A11780079F

Q33375062-55DF9445-9E88-4257-A937-213BF53551B6

P304

Q33375062-303D4476-4E36-4F0B-9261-85B9BCA77B93

P31

Q33375062-A18DE638-415B-4426-BD19-C54DA66404DC

P356

Q33375062-223683A5-9263-45C2-9B62-5C6EC1D590FD

P433

Q33375062-5AC03038-A1C8-418B-8881-5D3591E1E4D6

P478

Q33375062-7770F69A-8492-470F-828E-AC1ADCDF12ED

P50

Q33375062-861A4828-AF9F-43AD-B04B-3571E700A7C3

P577

Q33375062-4024BF9B-288A-42CC-B43A-36A9E58FB4E0

P5875

Q33375062-69708CF2-9B6F-42DD-A909-1D6D34F702CA

P698

Q33375062-BA04355B-91C7-4D6E-8C3E-2C8A780EB282

P921

Q33375062-96CF0ED8-8D66-431F-A6C3-9E9F5CBC8134

Q33375062-CC830248-063F-4567-B33A-3715627E2D6F

P356

J.1537-2995.2007.01208.X

P1433

P1476

Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.

@en

P2093

Cedric Ghevaert

http://www.w3.org/2001/XMLSchema#string

Dave Allen

http://www.w3.org/2001/XMLSchema#string

Edmund Ranasinghe

http://www.w3.org/2001/XMLSchema#string

Graham A Smith

http://www.w3.org/2001/XMLSchema#string

Jill Walton

http://www.w3.org/2001/XMLSchema#string

Kate Campbell

http://www.w3.org/2001/XMLSchema#string

Lorna M Williamson

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis of collagen recognition by integrin alpha2beta1

Nomenclature of human platelet antigens

348 CASES OF SUSPECTED NEONATAL ALLOIMMUNE THROMBOCYTOPENIA

A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti-HPA-1a.

Management of severe alloimmune thrombocytopenia in the newborn.

Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn.

Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens.

Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia.

A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia.

HPA-1a phenotype-genotype discrepancy reveals a naturally occurring Arg93Gln substitution in the platelet beta 3 integrin that disrupts the HPA-1a epitope.

P304

901-910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1537-2995.2007.01208.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Willem H Ouwehand

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6363894

http://www.w3.org/2001/XMLSchema#string

P698

17465957

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia

maternal health